IL298510A - Genetically modified natural killer cells for CD70-tuned cancer immunotherapy - Google Patents

Genetically modified natural killer cells for CD70-tuned cancer immunotherapy

Info

Publication number
IL298510A
IL298510A IL298510A IL29851022A IL298510A IL 298510 A IL298510 A IL 298510A IL 298510 A IL298510 A IL 298510A IL 29851022 A IL29851022 A IL 29851022A IL 298510 A IL298510 A IL 298510A
Authority
IL
Israel
Prior art keywords
cells
cdr
seq
sequence
chain variable
Prior art date
Application number
IL298510A
Other languages
English (en)
Hebrew (he)
Inventor
James Barnaby Trager
Alexandra Leida Liana Lazetic
Ivan Chan
Chao Guo
Katherine Jamboretz
Original Assignee
Nkarta Inc
James Barnaby Trager
Alexandra Leida Liana Lazetic
Ivan Chan
Chao Guo
Katherine Jamboretz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nkarta Inc, James Barnaby Trager, Alexandra Leida Liana Lazetic, Ivan Chan, Chao Guo, Katherine Jamboretz filed Critical Nkarta Inc
Publication of IL298510A publication Critical patent/IL298510A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL298510A 2020-06-12 2021-06-10 Genetically modified natural killer cells for CD70-tuned cancer immunotherapy IL298510A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063038645P 2020-06-12 2020-06-12
US202063090041P 2020-10-09 2020-10-09
US202163141411P 2021-01-25 2021-01-25
US202163201490P 2021-04-30 2021-04-30
PCT/US2021/036879 WO2021252804A1 (en) 2020-06-12 2021-06-10 Genetically modified natural killer cells for cd70-directed cancer immunotherapy

Publications (1)

Publication Number Publication Date
IL298510A true IL298510A (en) 2023-01-01

Family

ID=78846545

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298510A IL298510A (en) 2020-06-12 2021-06-10 Genetically modified natural killer cells for CD70-tuned cancer immunotherapy

Country Status (10)

Country Link
US (2) US12012458B2 (https=)
EP (1) EP4165171A4 (https=)
JP (1) JP7824894B2 (https=)
KR (1) KR20230024984A (https=)
AU (1) AU2021286655A1 (https=)
BR (1) BR112022025295A2 (https=)
CA (1) CA3184752A1 (https=)
IL (1) IL298510A (https=)
MX (1) MX2022015586A (https=)
WO (1) WO2021252804A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2021252804A1 (en) 2020-06-12 2021-12-16 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
EP4232465A4 (en) * 2020-10-26 2024-10-23 Memorial Sloan Kettering Cancer Center Cells with cd70 knockout and uses for immunotherapy
CA3201499A1 (en) * 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
JP2023552998A (ja) * 2020-12-03 2023-12-20 ンカルタ・インコーポレイテッド 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
EP4277638A4 (en) * 2021-01-12 2024-12-04 Hadasit Medical Research Services&Development Ltd. ENHANCED ADOPTIVE CELL TRANSFER THERAPY FOR CANCER
WO2023154785A2 (en) * 2022-02-10 2023-08-17 Orionis Biosciences, Inc. Il-2 trap molecules
CA3254363A1 (en) * 2022-03-07 2023-09-14 Nkarta, Inc. Multiplex gene-edited cells for CD70-led cancer immunotherapy
CN115925923B (zh) * 2022-09-26 2023-09-15 吉林大学 一种催化Aβ42寡聚体降解的单链抗体、单链抗体基因及其应用
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN116445416B (zh) * 2023-06-08 2023-10-17 山东兴瑞生物科技有限公司 一种基因修饰的car-nk细胞及其制备方法和应用
WO2024251290A1 (en) * 2023-06-09 2024-12-12 Suzhou Cure Genetics Biosciences Co., Limited Engineered immune cells and uses thereof
WO2025038637A1 (en) * 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
TW202515994A (zh) * 2023-08-14 2025-04-16 美商英特利亞醫療公司 用於對ｃｄ７０進行基因修飾之組合物及方法
AU2024324870A1 (en) * 2023-08-14 2026-02-12 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022311A1 (en) 1996-05-21 2003-01-30 Dunnington Damien D. Human CIS protein
US6323317B1 (en) 1996-11-01 2001-11-27 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostics proteins comprising a SOCS box
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
CA2480052A1 (en) * 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
JP2008522951A (ja) 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US7868159B2 (en) 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
EP1940460A4 (en) * 2005-10-27 2009-08-12 Biogen Idec Inc OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
WO2008060331A2 (en) * 2006-05-19 2008-05-22 Amgen Inc. Antibodies to sars coronavirus
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US20120192298A1 (en) 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
WO2012078540A1 (en) 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1
EP4303232A3 (en) 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
CA2932547C (en) * 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
ES3063961T3 (en) * 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
MX373460B (es) 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
AU2015259877B2 (en) * 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
US10100118B2 (en) * 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
KR102438360B1 (ko) 2016-03-04 2022-08-31 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
EP3519443A4 (en) 2016-09-30 2020-06-10 Baylor College of Medicine CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
CA3041831A1 (en) 2016-10-27 2018-05-03 Intima Bioscience, Inc. Viral methods of making genetically modified cells
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
US20180100016A1 (en) 2016-12-22 2018-04-12 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
CN118271442A (zh) * 2016-12-23 2024-07-02 蓝鳍生物医药公司 抗sez6l2抗体和抗体药物缀合物
JP2020503043A (ja) 2016-12-30 2020-01-30 セルラリティ インコーポレイテッド 遺伝子改変されたナチュラルキラー細胞
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11497768B2 (en) * 2017-06-05 2022-11-15 Mie University Antigen-binding protein that recognizes MAGE-A4-derived peptide
SG11201912010XA (en) * 2017-06-12 2020-01-30 Obsidian Therapeutics Inc Pde5 compositions and methods for immunotherapy
WO2019006418A2 (en) * 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
CN111788301A (zh) * 2017-11-24 2020-10-16 昂克治疗有限公司 靶向肿瘤细胞的经修饰的自然杀伤细胞和自然杀伤细胞系
KR102780406B1 (ko) * 2018-02-01 2025-03-17 화이자 인코포레이티드 Cd70을 표적으로 하는 키메라 항원 수용체
MX2020009272A (es) 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
CN110351878B (zh) * 2018-04-04 2023-07-14 华为技术有限公司 一种随机接入处理方法和相关设备
US12227763B2 (en) 2018-05-11 2025-02-18 Crispr Therapeutics Ag Methods and compositions for treating cancer
JP2021530223A (ja) * 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
US20210338727A1 (en) * 2018-09-13 2021-11-04 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
JP7629414B2 (ja) 2019-06-04 2025-02-13 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
CA3144871A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
US12344656B2 (en) 2019-09-06 2025-07-01 Crispr Therapeutics Ag Genetically engineered T cells having improved persistence in culture
IL292467A (en) 2019-11-13 2022-06-01 Crispr Therapeutics Ag Treatment of hematopoietic cell cancers using genetically engineered t cells targeting cd70
BR112022009137A2 (pt) 2019-11-13 2022-07-26 Crispr Therapeutics Ag Métodos de fabricação de células t com receptor de antígeno quimérico (car)
BR112022009204A2 (pt) 2019-11-13 2022-07-26 Crispr Therapeutics Ag Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70
KR20220119038A (ko) 2019-11-25 2022-08-26 케이에스큐 세러퓨틱스 인코포레이티드 종양 침윤 림프구의 활성화 및 확장을 위한 방법
CN115297890A (zh) 2020-02-03 2022-11-04 国立大学法人东海国立大学机构 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物
WO2021231773A1 (en) * 2020-05-13 2021-11-18 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
WO2021252804A1 (en) 2020-06-12 2021-12-16 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
JP2023536818A (ja) 2020-07-29 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
CN116322716A (zh) 2020-09-23 2023-06-23 克里斯珀医疗股份公司 Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
JP2023552998A (ja) * 2020-12-03 2023-12-20 ンカルタ・インコーポレイテッド 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
AR125852A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
WO2022238962A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
CA3254363A1 (en) 2022-03-07 2023-09-14 Nkarta, Inc. Multiplex gene-edited cells for CD70-led cancer immunotherapy

Also Published As

Publication number Publication date
US20240360234A1 (en) 2024-10-31
US20220002424A1 (en) 2022-01-06
JP2023530408A (ja) 2023-07-18
BR112022025295A2 (pt) 2023-04-25
JP7824894B2 (ja) 2026-03-05
US12012458B2 (en) 2024-06-18
AU2021286655A1 (en) 2023-01-05
EP4165171A1 (en) 2023-04-19
KR20230024984A (ko) 2023-02-21
EP4165171A4 (en) 2025-03-26
WO2021252804A1 (en) 2021-12-16
CA3184752A1 (en) 2021-12-16
MX2022015586A (es) 2023-03-15

Similar Documents

Publication Publication Date Title
US12012458B2 (en) Genetically modified natural killer cells for CD70-directed cancer immunotherapy
JP7629414B2 (ja) 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
US20240335536A1 (en) Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
US20230390392A1 (en) Multiplex gene edited cells for cd70-directed cancer immunotherapy
US20250319185A1 (en) Bcma-directed cellular immunotherapy compositions and methods
KR20250046298A (ko) 자연 살해 세포 기능을 향상시키기 위한 표적 유전자의 유전자 편집
JP2023542528A (ja) Ｓｏｘ２抗原を標的とする免疫療法
EP4649139A1 (en) Methods for expanding immune cells and related compositions and uses thereof
CN116783288A (zh) 用于cd70定向癌症免疫疗法的基因修饰的自然杀伤细胞
WO2023220718A1 (en) Binding proteins specific for ras neoantigens and uses thereof
CN116940367A (zh) 工程化改造免疫细胞用于增强的效力和持久性的方法以及工程化细胞在免疫疗法中的用途